Postmenopausal osteoporosis (PMO) is a serious public health concern due to its silent nature, its first presentation as a fracture in majority of cases, significant morbidity and mortality caused by fractures and their complications, compromised quality of life and heavy economic burden on the individual, the society and the country. The use of currently available anti-osteoporotic agents is restricted many a times by their side effects. HT has fallen out of favor to a significant extent after the publication of the Women\'s Health Initiative Study results. Following the ever-evolving need of the society and by virtue of its inherent nature, research continues to look for ideal agents for the management of all medical conditions with an aim to improve efficacy and reduce adverse effects. So is the case with PMO.

This is a small but well-conducted open-label study. The outcomes have been encouraging in the form of anti-osteoporotic and anti-inflammatory properties of the Standardized Extract of Leaves of *Dalbergia sissoo* for PMO with a favorable safety profile in fixed doses. The potential anti-arthritic property of the drug is evident not only by a fall in the marker but also by a significant improvement in musculoskeletal symptoms. However, the dropout rate was higher than an acceptable \<10%. Like the authors have also mentioned, a flexible dose schedule needs to be studied while ascertaining the effect of the drug on bone-specific markers. The newer drug needs to be studied in depth in terms of interactions with other agents, cost effectiveness, etc.

This should form the basis of larger randomized controlled trials to further study this seemingly promising new drug.
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